Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

Running, not enrolling · Phase 1/Phase 2

Conditions studied: X-Linked Retinitis Pigmentosa

In brief

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.

Key facts

Study ID

NCT03316560

Run by

Beacon Therapeutics

People needed

29

Starts

2018-04-16

Expected to finish

2025-03-01

Last updated by the study team

2024-05-20

Who can join

Age: 6 and older, up to 50. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Duke University — Durham, North Carolina, United States
• Cincinnati Eye Institute — Cincinnati, Ohio, United States
• Casey Eye Institute — Portland, Oregon, United States
• Retina Foundation of the Southwest — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.